01 Jul 2025
Labcorp has launched two innovative liquid biopsy tests—Labcorp Plasma Detect and PGDx Elio Plasma Focus Dx—to advance cancer detection and treatment. Plasma Detect uses whole genome sequencing to identify molecular residual disease (MRD) in stage III colon cancer patients, while the FDA-authorized Elio Plasma Focus Dx offers rapid, pan-solid tumor profiling to guide targeted therapies. These additions strengthen Labcorp’s precision oncology portfolio and aim to improve outcomes through earlier, less invasive detection. Read the full article in CAP TODAY.